Please login to the form below

Not currently logged in
Email:
Password:

DBV Therapeutics

This page shows the latest DBV Therapeutics news and features for those working in and with pharma, biotech and healthcare.

FDA knocks back DBV’s peanut allergy therapy once again

FDA knocks back DBV’s peanut allergy therapy once again

Drug loses further ground to Aimmune's Palforzia. DBV Technologies’ struggle to get its peanut allergy therapy approved looks set to drag on, after the US Food and Drug Administration (FDA) ... The setback means that DBV’s drug loses further ground

Latest news

  • Aimmune’s Palforzia is first peanut allergy drug cleared in US Aimmune’s Palforzia is first peanut allergy drug cleared in US

    California biotech Aimmune has been in a race to market with rival companies like France’s DBV Technologies, which filed for approval of its Viaskin Peanut skin patch-based product at ... DBV’s share price in the last few weeks.

  • DBV refiles peanut allergy immunotherapy in the US DBV refiles peanut allergy immunotherapy in the US

    DBV says its new filing “incorporates additional data needs on manufacturing procedures and quality controls” requested by the agency. ... GlobalData has predicted that Aimmune’s drug will have two-thirds of the market in 2027, with DBV’s drug

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics